419 related articles for article (PubMed ID: 21770378)
1. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Peura L; Malmioja K; Laine K; Leppänen J; Gynther M; Isotalo A; Rautio J
Mol Pharm; 2011 Oct; 8(5):1857-66. PubMed ID: 21770378
[TBL] [Abstract][Full Text] [Related]
2. Large neutral amino acid transporter enables brain drug delivery via prodrugs.
Gynther M; Laine K; Ropponen J; Leppänen J; Mannila A; Nevalainen T; Savolainen J; Järvinen T; Rautio J
J Med Chem; 2008 Feb; 51(4):932-6. PubMed ID: 18217702
[TBL] [Abstract][Full Text] [Related]
3. Brain uptake of ketoprofen-lysine prodrug in rats.
Gynther M; Jalkanen A; Lehtonen M; Forsberg M; Laine K; Ropponen J; Leppänen J; Knuuti J; Rautio J
Int J Pharm; 2010 Oct; 399(1-2):121-8. PubMed ID: 20727958
[TBL] [Abstract][Full Text] [Related]
4. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
5. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).
Ylikangas H; Malmioja K; Peura L; Gynther M; Nwachukwu EO; Leppänen J; Laine K; Rautio J; Lahtela-Kakkonen M; Huttunen KM; Poso A
ChemMedChem; 2014 Dec; 9(12):2699-707. PubMed ID: 25205473
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
Peura L; Malmioja K; Huttunen K; Leppänen J; Hämäläinen M; Forsberg MM; Gynther M; Rautio J; Laine K
Pharm Res; 2013 Oct; 30(10):2523-37. PubMed ID: 24137801
[TBL] [Abstract][Full Text] [Related]
7. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.
Puris E; Gynther M; Huttunen J; Petsalo A; Huttunen KM
J Control Release; 2017 Sep; 261():93-104. PubMed ID: 28662899
[TBL] [Abstract][Full Text] [Related]
8. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats.
Gynther M; Ropponen J; Laine K; Leppänen J; Haapakoski P; Peura L; Järvinen T; Rautio J
J Med Chem; 2009 May; 52(10):3348-53. PubMed ID: 19402664
[TBL] [Abstract][Full Text] [Related]
9. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
Huttunen J; Peltokangas S; Gynther M; Natunen T; Hiltunen M; Auriola S; Ruponen M; Vellonen KS; Huttunen KM
Sci Rep; 2019 Sep; 9(1):12860. PubMed ID: 31492955
[TBL] [Abstract][Full Text] [Related]
10. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.
Montaser AB; Järvinen J; Löffler S; Huttunen J; Auriola S; Lehtonen M; Jalkanen A; Huttunen KM
ACS Chem Neurosci; 2020 Dec; 11(24):4301-4315. PubMed ID: 33228353
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.
Ylikangas H; Peura L; Malmioja K; Leppänen J; Laine K; Poso A; Lahtela-Kakkonen M; Rautio J
Eur J Pharm Sci; 2013 Feb; 48(3):523-31. PubMed ID: 23228412
[TBL] [Abstract][Full Text] [Related]
12. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.
Gynther M; Peura L; Vernerová M; Leppänen J; Kärkkäinen J; Lehtonen M; Rautio J; Huttunen KM
Neurochem Res; 2016 Oct; 41(10):2797-2809. PubMed ID: 27412117
[TBL] [Abstract][Full Text] [Related]
13. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
Rautio J; Kärkkäinen J; Huttunen KM; Gynther M
Eur J Pharm Sci; 2015 Jan; 66():36-40. PubMed ID: 25305508
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets.
Puris E; Gynther M; de Lange ECM; Auriola S; Hammarlund-Udenaes M; Huttunen KM; Loryan I
Mol Pharm; 2019 Jul; 16(7):3261-3274. PubMed ID: 31180686
[TBL] [Abstract][Full Text] [Related]
15. Prodrug design for brain delivery of small- and medium-sized neuropeptides.
Prokai-Tatrai K; Prokai L
Methods Mol Biol; 2011; 789():313-36. PubMed ID: 21922418
[TBL] [Abstract][Full Text] [Related]
16. Carrier-mediated delivery of metabotrophic glutamate receptor ligands to the central nervous system: structural tolerance and potential of the L-system amino acid transporter at the blood-brain barrier.
Reichel A; Begley DJ; Abbott NJ
J Cereb Blood Flow Metab; 2000 Jan; 20(1):168-74. PubMed ID: 10616805
[TBL] [Abstract][Full Text] [Related]
17. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
Kärkkäinen J; Gynther M; Kokkola T; Petsalo A; Auriola S; Lahtela-Kakkonen M; Laine K; Rautio J; Huttunen KM
Int J Pharm; 2018 Jun; 544(1):91-99. PubMed ID: 29669256
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs.
More SS; Vince R
J Med Chem; 2008 Aug; 51(15):4581-8. PubMed ID: 18651729
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells.
Patel M; Dalvi P; Gokulgandhi M; Kesh S; Kohli T; Pal D; Mitra AK
Int J Pharm; 2013 Feb; 443(1-2):245-53. PubMed ID: 23270998
[TBL] [Abstract][Full Text] [Related]
20. Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).
Helms HCC; Kristensen M; Saaby L; Fricker G; Brodin B
Handb Exp Pharmacol; 2022; 273():151-183. PubMed ID: 33367937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
